Filed Under: Potency Trap

Cannabis did not become harder to understand because the plant got stronger.
It became harder to understand because the people with power over the plant found the same lazy shortcut. Politicians used THC percentage to scare the public. Dispensaries used THC percentage to sell flower. Consumers learned to shop by THC percentage because the market trained them to do it.
Somewhere inside that loop, quality got flattened into a number. A percentage can tell part of the story, but it cannot explain cure, freshness, balance, tolerance, route of use, or the person consuming it.
Fear and sales both needed a simple handle.
In Britain, that handle was “skunk.”
A public listing for the BBC Three documentary Should I Smoke Dope? describes journalist Nicky Taylor going to Amsterdam, helping out in a coffeeshop, and returning to the United Kingdom to examine “skunk.” The listing frames the film around stronger cannabis and alcohol comparison, the fear that cannabis could make someone “crazy,” and a month-long experiment.
Viewed now, the documentary plays less like settled cannabis science than a cultural artifact from a country trying to turn potency into a moral verdict.
The timing was not neutral. On May 7, 2008, the Advisory Council on the Misuse of Drugs published its cannabis classification report. The report followed a request from the Home Secretary, who cited “real public concern” about mental health effects and stronger cannabis, commonly known as skunk. The government still moved cannabis back from Class C to Class B. The Guardian reported in 2009 that the Home Secretary had overruled ACMD advice, the previous May, that cannabis should remain Class C.
“Skunk” carried the politics. It gave the public a villain, gave officials a harder-sounding word than cannabis, and let newspapers treat stronger flower like a different drug.
Higher-THC cannabis exists. Denying that helps nobody. Axios, citing National Institute on Drug Abuse data, summarized the U.S. shift from seized cannabis averaging under 4 percent THC in 1995 to more than 16 percent in 2022.
Stronger products can change the experience. A new user taking one pull from low-THC flower is not in the same position as a daily concentrate consumer. A returning user eating a 10-milligram edible after years away from cannabis faces another situation entirely.
Dose and tolerance shape the result. So do frequency, delivery method, product type, body chemistry, setting, and expectation.
Prohibition skips that complexity. It points to higher THC as proof of danger.
The market points to higher THC as proof of value.
Neither version understands the plant.
Cannabis literacy should have moved in the opposite direction. Legalization should have given consumers more language, not less. A regulated market had the chance to teach people how flower change from harvest to shelf. Cure could have become part of the conversation. Freshness could have mattered more than the biggest number on the menu. Balance could have been treated as a real selling point instead of an afterthought.
Instead, too many menus trained buyers to scan for the biggest number first.
That habit is not harmless. Once THC becomes the main signal, everything else has to fight for attention. A good flower with a lower number gets treated like a lesser product. Balanced flower gets treated like a niche. The buyer who wants something functional has to work harder. So does the buyer look for a social, creative, or manageable experience.
That is backwards.
A THC percentage says something limited. It tells the buyer how much tetrahydrocannabinol was measured in a sample under a particular testing system. For flower, the number can help with broad potency awareness. For edibles, milligram labeling can help people avoid overconsumption when labels are accurate, and consumers understand delayed onset.
After that, the number starts getting credit it never earned.
Cannabis is not alcohol. One percent cannot carry the whole dosing burden. Flower is a chemical system shaped long before the label. Growing and drying leaves a mark. So do curing, packaging, storage, heat, light, and time. THC is central to intoxication. It is not the whole experience.
Commercial cannabis science keeps making that point.
A 2022 PLOS One study analyzed 89,923 commercial cannabis-derived flower samples from six U.S. states. The study found that familiar labels such as indica, hybrid, and sativa did not consistently align with the chemical diversity observed in the samples. It also reported that 96.5 percent of samples in the aggregate dataset were THC-dominant. CBD-dominant and balanced THC-to-CBD samples made up far smaller shares.
The study exposes two problems at once.
M O R E F R O M P O T C U L T U R E M A G A Z I E
CANNABIS LIES Vol. 7: The Mental Health Panic
Cannabis and mental health risks are often overstated in public debate. Research shows heavy use and high THC exposure can increase psychosis risk in vulnerable individuals, but widespread claims of a mental health crisis lack strong evidence. This piece examines the data, separates correlation from causation, and breaks down what cannabis users need to know.
THE CANNABIS LIE: Vol. 1
This new investigative series begins by confronting one of cannabis policy’s most durable myths. THC percentage became a convenient shortcut for harsher laws, even though higher potency has never equaled greater danger. Vol. 1 documents how numbers replaced evidence and how courts, media, and policy still punish people for a claim that cannot survive scrutiny.
Reefer Report Card Vol. 27: The System Shows Its Teeth
This week’s Reefer Report Card exposes a system under strain as federal hemp policy whiplashes, New York’s cannabis regulator unravels, and Massachusetts stirs panic over THC potency. Patients and workers absorb the fallout while international reform stalls under bureaucratic drag. Cannabis holds steady. Governance does not.
Old strain language is unreliable. A package calling something indica does not prove how it will feel. A sativa label does not guarantee energy. Hybrid has become so broad that it often means little beyond “not marketed as the other two.”
Legal shelves also narrowed the chemical field. When nearly everything offered to consumers is THC-dominant, cannabis gets treated as stronger or weaker. Balanced flower becomes a specialty item. CBD-rich flower gets pushed into another lane. Terpene profiles and minor cannabinoids get shoved behind the headline number.
Retail shorthand is not cannabis literacy.
The damage is cultural, too. Cannabis has always carried knowledge outside official systems. People learned from growers, friends, patients, dealers, caregivers, and budtenders. They also learned from bad experiences. Some of that knowledge was rough. Some of it was folklore. Some of it was dead accurate because it came from lived use instead of policy panic.
Legalization should have refined that knowledge by separating myth from experience, then separating experience from marketing.
The THC race did the opposite. It gave consumers a legal market with lab coats on the label and casino logic in the sales case.
The sales logic was simple: bigger number, higher price, faster sale.
That is not reform. That is reduction.
The same PLOS One paper described cannabis as chemically diverse. It also warned that consumer marketing and product classification are often divorced from the chemical reality of the material being sold.
The word “entourage” has been beaten into marketing paste, so it has to stay on a short leash.
Whole-plant experience is not a fantasy. Researchers have noted that distinct chemovars with different cannabinoid and terpene ratios are hypothesized to cause distinct effects for consumers. The same PLOS One paper makes a narrower point. Cannabis classification, consumer marketing, and research still need stronger chemistry-based standards.
Both things can be true without turning science into sales copy.
The whole flower may matter. Chemical balance may matter too. Terpenes, CBD content, curing, and freshness can shape what users smell, taste, and feel. Commercial “full-spectrum” language still deserves suspicion when the product is priced and promoted mainly by THC.
The old market had its own lies. Legacy weed could be seeded, compressed, stale, or moldy. Some of it was sprayed or badly grown. Nobody needs to pretend every bag from the past was sacred medicine wrapped in sandwich plastic.
Some of it was garbage, and some of it was excellent.
Most people learned the difference through use. Smell told part of the story. Texture told another. Burn, taste, trust, and experience did the rest.
Imperfect knowledge is not stupidity.
A buyer could smell hay and know the cure was bad. Dry flower warned the hand before it hit the bowl. Sticky buds with a clean nose meant something before a lab label ever existed. Good cannabis had presence. It was not only “strong.” It had a face.
Legalization should have improved that literacy. Testing should have protected consumers from contaminants, false labels, and mystery products. Regulated stores should have made flower easier to compare by more than rumor.
Instead, the market rewarded the fastest number.
High-THC flower became easier to sell, while low-THC flower became harder to explain. Balanced flower had to justify itself. Growers faced pressure to chase lab results because shelf placement, price, and consumer attention often followed the biggest percentage on the jar.
Then the label problem got louder.
Axios reported in July 2025 that a University of Colorado Boulder study found nearly half of tested Colorado cannabis flower products overstated THC content on labels. Researchers tested 277 products from 52 dispensaries across 19 counties. Senior author Cinnamon Bidwell warned that THC-focused labeling can do consumers a disservice because other cannabinoids should also be reported.
The THC race became a trust problem.
When a product wins attention because the label says 31 percent, the lab number becomes a sales tool. Inflated or inconsistent results turn that tool into a distortion machine. Consumers think they are comparing quality. Too often, they are comparing paperwork.
Testing was supposed to pull cannabis out of the dark. Bad incentives can drag the numbers right back into the mud.
The lab problem does not mean testing is bad. Testing is necessary. Consumers deserve contaminant screening and accurate labels. They also deserve a market that does not ask them to trust a mystery flower wrapped in professional packaging.
The problem is incentive. When higher THC can mean better shelf placement, easier sales, or a higher price, the pressure becomes significant. Growers, labs, retailers, and consumers all feel that pressure at the counter.
A clean legal market cannot run on a number that everyone has reason to inflate, chase, or misunderstand.
Connecticut offered another example. CT Insider reported in 2025 that a Massachusetts lawsuit accused several cannabis testing labs of inflating THC results and minimizing contaminants to attract clients. The complaint described “lab shopping,” where producers seek laboratories that deliver favorable results. CT Insider reported that Analytics Labs was one of eight laboratories named in the Massachusetts lawsuit. The outlet also reported that the lab did not return a request for comment and had not yet filed a rebuttal as of the report.
Legal weed did not invent potency worship. It professionalized it.
Prohibition built the fear language first. “Not your parents’ marijuana” became one of the oldest modern scare lines in cannabis politics. Britain had “skunk.” The United States had rising potency charts. Every era found a way to make the next version of cannabis sound newly terrifying.
Then the regulated market sold the same fear number as a premium feature.
The hypocrisy is almost too clean. Anti-cannabis officials told the public that high-THC meant danger. Cannabis retailers told the public that high-THC meant value. The two sides sounded opposed, but both trained people to stare at the same number.
Potency is not irrelevant.
Strong THC products can create an unpleasant acute experience, especially when a consumer takes more than intended. Edibles deserve special caution because delayed onset can lead people to redose too soon, a risk documented in a medical review on cannabis edibles and intoxication.
A pro-cannabis publication does not need to dodge that.
Accuracy matters more than comfort. Risk is not prohibition. Education is not panic. A regulated product can be strong without being evil. A consumer can be warned without being shamed. Cannabis can be defended without pretending every product is gentle.
The route of use alone shows how thin the THC number can be. Smoked or vaporized cannabis acts quickly, so many users can adjust intake in real time. Edibles move through digestion. They take longer to appear and can last longer. That delay can lead people to redose too soon. A medical review on cannabis edibles and intoxication notes that a delayed onset can lead users to consume more than intended.
A small dab, a joint, a gummy, and a tincture do not belong in one consumer education box.
The label may show THC. The body still decides the experience.
Curing also gets erased by percentage shopping. A rushed dry can leave flower harsh and green. Poor storage can flatten aroma and degrade cannabinoids. Heat, light, oxygen, and time can change the plant after harvest. The PLOS One study notes that CBN is a byproduct that accumulates with the breakdown of THC.
Old weed nostalgia often starts there.
People are not only remembering weaker cannabis. Many are remembering a different relationship to the plant. Smell came first. Source, cure, and smoke mattered. Nobody held up a jar and declared the batch good because a printed label won the math contest.
Memory can lie. It can also preserve what the market threw away.
A lot of older consumers are not asking for bad brick weed to come back. They are reacting to a legal market where flower can look perfect and still fall flat. It can test high and smoke hot. It can cost too much and smell faint. People remember cannabis with more personality than packaging.
Modern craft growers still exist. Some legal producers still care about the work after harvest, from genetics and soil to drying, curing, terpene preservation, and clean flower. Some of the best cannabis ever grown is being grown now.
The problem is not modern cannabis.
Modern cannabis has advantages the old market never had. Clean facilities and testing protect consumers. Better genetics, patient access, consistent dosing, and legal purchase options changed the ground.
This is not nostalgia dressed up as criticism.
The past had bad weed, bad storage, dirty supply chains, and plenty of guesswork. Nostalgia can turn memory into myth if nobody checks it. But memory is not useless. Older consumers often name a real loss, even when they describe it imperfectly.
They are talking about the loss of plant literacy: cannabis that smelled alive, flower that smoked clean, and a plant that carried more identity than a number on a jar.
That does not mean old weed was always better. It means modern weed should be smart enough not to sell itself like a scoreboard.
The problem is a market that often makes the best work harder to identify because the loudest number keeps cutting the line.
A 24 percent flower with a proper cure can beat a brittle 32 percent batch. The lower number may have a better nose. It may smoke cleaner. It may carry a fuller effect.
Consumers know this once they experience it. The market hopes they forget before checkout.
The BBC’s 2008 panic artifact and the modern dispensary menu are not as far apart as they look. One turned THC into a warning sign. The other turned THC into a price signal. Neither taught the public how to understand the plant.
Cannabis deserved better from both.
The better standard is not anti-potency. Strong cannabis has a place. Medical cannabis patients may need high-THC products. Experienced consumers may prefer them. Concentrates have a place. So do edibles, tinctures, hash, flower, and balanced products. A mature cannabis culture can hold all of that when consumers know what they are taking and why.
The failure comes from pretending strength equals quality.
Quality starts before the label. Genetics and cultivation come first. Cure and storage shape what survives. Testing integrity, freshness, aroma, chemistry, and intended use finish the picture.
Then the person enters the equation.
A THC percentage cannot answer all of that. It was never built to.
Used carefully, the number can warn a novice, guide dosing, and help researchers track market shifts.
Used as the main definition of cannabis, it breaks the conversation.
Prohibition broke it by turning potency into a scare word. The industry broke it again by turning potency into a sales race. Consumers got stuck between the sermon and the menu, told to fear the number by one side and chase it by the other.
Cannabis culture knows better because cannabis culture has always known the plant is more than one measurement.
A good batch announces itself before the math does.
The nose opens first. The cure and burn fill in the rest. The effect arrives through the person using it, not through the label alone.
No lab percentage can carry all of that.
THC did not break weed.
The number did.
©2026 Pot Culture Magazine. All rights reserved. This content is the exclusive property of Pot Culture Magazine and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission from the publisher, except for brief quotations in critical reviews.
F O R T H E C U L T U R E B Y T H E C U L T U R E
Cannabis Lies Vol. 15: The Lab-Tested Lie
Lab-tested cannabis sounds clean until recalls, weak state rules, bad lab reporting, and inflated THC numbers expose the limits behind the sticker. Cannabis Lies Vol. 15 breaks down why legal testing still matters, why regulation beats blind-market guessing, and why no cannabis COA should be treated like proof that every risk disappeared.
Cannabis Lies Vol. 14: The Fentanyl Weed Lie
Cannabis Lies Vol. 14 dismantles the fentanyl-laced weed rumor with New York public-health guidance, DEA fentanyl data, CDC overdose statistics, and the Connecticut case often used to inflate the panic. The article separates real fentanyl risks from unsupported cannabis scare tactics and shows how prohibition turns an opioid crisis into a marijuana myth.
Prohibition Is Running Out of Voters
Pew’s May 26, 2026 report says only 11 percent of U.S. adults want marijuana illegal in all cases. Pot Culture Magazine examines what that means for cannabis legalization, federal marijuana law, employment testing, immigration policy, banking barriers, and the drug war machinery still protecting prohibition after the public moved on.
Discover more from POT CULTURE MAGAZINE
Subscribe to get the latest posts sent to your email.
This is all so true. It’s also compounded by the fact that, in a number of states, retailers aren’t even allowed to let consumers see or smell the product before buying. They get a digitized menu, with a big, bold THC percentage next to a fancy new strain name and a picture, of… the packaging! Not the plant. A picture of the packaging. Maybe in some locations a nug is displayed under glass but it might not even be the same product. Consumers won’t ever get to smell what they’re buying and so often, when it comes to flower, the nose knows! Perhaps, someday, when the novelty of store bought weed wears off, this will change. But, as you write here, damage is being done now and repairing that will take a long, long time.